Ads
related to: when should simvastatin be takengoodrx.com has been visited by 100K+ users in the past month
"Shop around for the best prices without a membership fee." - Today
consumereview.org has been visited by 100K+ users in the past month
Search results
Results from the WOW.Com Content Network
Simvastatin, sold under the brand name Zocor among others, is a statin, a type of lipid-lowering medication. [4] It is used along with exercise, diet, and weight loss to decrease elevated lipid levels. [4] It is also used to decrease the risk of heart problems in those at high risk. [4] It is taken by mouth. [4]
Heart doctors warned, however, that more information is needed and patients shouldn’t stop taking their medications. Statins, such as Lipitor, Crestor and Zocor, are widely used to protect ...
[22] [23] Another consequence of taking statins is the risk of developing new-onset diabetes, which is more prominent in individuals with high TG levels and body mass index (BMI). [19] However, the risk is far outweighed by the benefits from statin therapy for the reduction in cardiovascular outcomes. [20]
Statins are generally recommended for adults between the ages of 40 and 75 who have heart disease risk factors. Despite having higher risks for cardiovascular disease, fewer older adults use statins.
Statins are a medication type that can help people at risk for atherosclerotic cardiovascular disease. Doctors look at several factors to determine if statin therapy makes the most sense for someone.
Statins may improve quality of life when used in people without existing cardiovascular disease (i.e. for primary prevention). [74] Statins decrease cholesterol in children with hypercholesterolemia, but no studies as of 2010 show improved outcomes [ 76 ] and diet is the mainstay of therapy in childhood.
Possibly taking certain medications during pregnancy, such as statins. Possibly smoking or drinking during pregnancy. Poorly controlled diabetes during pregnancy. Certain genetic syndromes.
With median follow-up of 6 years, simvastatin+ezetimibe was found to reduce the primary outcome of CV mortality, major CV event, or nonfatal stroke (34.7% vs. 32.7%; P=0.016; NNT 50 per 7 years or NNT 350 per 1 year ). There was no reduction in all-cause or CV mortality with simvastatin+ezetimibe, though there was a reduction in MI and stroke. [6]